| MicroRNAs in melanoma development and resistance to target therapy L Fattore, S Costantini, D Malpicci, CF Ruggiero, PA Ascierto, CM Croce, ... Oncotarget 8 (13), 22262, 2017 | 100 | 2017 |
| Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma L Fattore, CF Ruggiero, ME Pisanu, D Liguoro, A Cerri, S Costantini, ... Cell Death & Differentiation 26 (7), 1267-1282, 2019 | 62 | 2019 |
| Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma L Fattore, CF Ruggiero, D Liguoro, R Mancini, G Ciliberto Cell death & disease 10 (11), 827, 2019 | 44 | 2019 |
| ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: early detection in CTCs during therapy and insights into regulation by … CF Ruggiero, D Malpicci, L Fattore, G Madonna, V Vanella, D Mallardo, ... Cancers 11 (10), 1425, 2019 | 27 | 2019 |
| The promise of liquid biopsy to predict response to immunotherapy in metastatic melanoma L Fattore, CF Ruggiero, D Liguoro, V Castaldo, A Catizone, G Ciliberto, ... Frontiers in Oncology 11, 645069, 2021 | 22 | 2021 |
| In vitro biophysical and biological characterization of lipid nanoparticles co-encapsulating oncosuppressors mir-199b-5p and mir-204-5p as potentiators of target therapy in … L Fattore, V Campani, CF Ruggiero, V Salvati, D Liguoro, L Scotti, G Botti, ... International Journal of Molecular Sciences 21 (6), 1930, 2020 | 22 | 2020 |
| Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma CF Ruggiero, L Fattore, I Terrenato, F Sperati, V Salvati, G Madonna, ... Theranostics 12 (17), 7420, 2022 | 13 | 2022 |
| Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance L Fattore, G Cafaro, M Di Martile, V Campani, A Sacconi, D Liguoro, ... Oncogene 42 (4), 293-307, 2023 | 9 | 2023 |
| Harnessing therapy resistant tumor microenvironment with lipid nanoparticles carrying miR-199b-5p and miR-204-5p to potentiate MAPKi in BRAF-mutant metastatic melanoma L Fattore, V Campani, E Marra, G Cafaro, D Liguoro, CF Ruggiero, ... JOURNAL OF TRANSLATIONAL MEDICINE 20 (SUPPL 1), 2022 | | 2022 |
| Circulating levels of miR-204-5p predict response to BRAF and MEK inhibitors in metastatic melanoma patients CF Ruggiero, I Terrenato, L Fattore, V Salvati, F Sperati, D Liguoro, ... JOURNAL OF TRANSLATIONAL MEDICINE 19 (SUPPL 1), 2021 | | 2021 |
| Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts D Carbone, M Sharpnack, K He, LH Butterfield, AMM Eggermont, ... Journal of Translational Medicine 16, 1-15, 2018 | | 2018 |
| MicroRNAs regulate resistance to target therapy in melanoma L Fattore, S Costantini, M Acunzo, G Romano, G Nigita, A Lagana, ... JOURNAL OF TRANSLATIONAL MEDICINE 15 (1), K8, 2017 | | 2017 |
| Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts V Hirsh, S Pignata, M Bersanelli, L Gnetti, C Azzoni, L Bottarelli, ... Journal of Translational Medicine 15, 1-14, 2017 | | 2017 |
